Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation. Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or the docetaxel treatment group. Participants in the PF-08046054 treatment group will receive an IV infusion (injected directly into the veins) twice during each 21-day cycle. Participants in the docetaxel treatment group will receive an IV infusion once during each 21-day cycle. Study participation may be up to 5 years if the participant's NSCLC is responding to treatment. The study team will see how each participant is doing with the study treatment during regular visits at the clinic.
Conditions Studied
Interventions
- DRUG PF-08046054
- DRUG Docetaxel monotherapy
Study Locations (20)
Alabama
- Alabama Oncology — Alabaster
- Alabama Oncology — Bessemer
- Alabama Oncology, Bruno Cancer Center — Birmingham
- Alabama Oncology — Birmingham
- Alabama Oncology — Birmingham
- Alabama Oncology — Birmingham
- Alabama Oncology — Birmingham
- Southern Cancer Center — Daphne
- Southern Cancer Center, PC — Foley
Arkansas
- Highlands Oncology Group, PA — Fayetteville
- Highlands Oncology Group, PA — Rogers
- Highlands Oncology Group, PA — Springdale
- Highlands Oncology Group — Springdale
California
- Providence Medical Foundation — Fullerton
- Providence St. Jude Medical Center — Fullerton
Florida
- Cancer Care Centers of Brevard, Inc. — Palm Bay
- Florida Cancer Affiliates - Panama City — Panama City
Alaska
- Alaska Oncology and Hematology — Anchorage
Colorado
- Rocky Mountain Cancer Centers,LLP — Denver
Delaware
- Medical Oncology Hematology Consultants, PA — Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 680 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2032-03-10 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144280
The ClinicalTrials.gov registry entry for NCT07144280 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 680 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Non-Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions — of which PF-08046054 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07144280 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Alabama, Arkansas, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07144280 about?
NCT07144280 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)". The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 in...
What is the current status of trial NCT07144280?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 680 participants. The study started on 2025-09-29. Estimated completion is 2032-03-10.
What conditions does trial NCT07144280 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Carcinoma, Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07144280?
The interventions under investigation include: PF-08046054 (DRUG), Docetaxel monotherapy (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07144280?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07144280 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.